• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves Philips’ low-dose Stellarex balloons

October 15, 2019 By Sean Whooley

philips-logoRoyal Philips (NYSE:PHG) said today that two of the company’s new Stellarex drug-coated balloons received FDA approval for the treatment of upper leg artery blockages.

The approval was for both de novo and restenotic lesions in upper leg arteries.

The Amsterdam-based company said the new low-dose (200 mm and 150 mm) balloons will be added to the Stellarex DCB portfolio to broaden options for treating peripheral artery disease in patients with a high risk of restenosis in the superficial femoral or popliteal arteries.

Royal Philips’ Stellarex DCBs include EnduraCoat, a coating made up of polyethylene glycol excipient with amorphous and crystalline paclitaxel particles designed to enable a low dosage. The balloons are available at lengths of 40, 60, 80, 100, 120, 150 and 200mm for the treatment of lesions in arteries with vessel diameters of 4–6 mm.

Earlier this month, Royal Philips touted data on the Stellarex balloons from a pivotal trial and a European randomized controlled trial, which altogether included 589 patients. Results showed that 2.3% of patients in the pivotal study and 3.7% in the E.U .RCT were lost to follow-up within the three years of the study.

Additional analysis included four Stellarex single-arm studies, which included 2,495 patients with peripheral artery disease, of which 2,325 were treated with Stellarex. The primary safety analysis showed no difference in mortality between Stellarex patients and patients treated with the standard uncoated PTA, while it also highlighted zero device-related deaths and no correlation of Stellarex to late all-case mortality.

The Stellarex DCB won FDA pre-market approval in June 2017. The new balloons are now available in the U.S. and Royal Philips said they will be brought to other markets in due time.

“With its unique coating, Stellarex is unlike any other DCB in the industry for the treatment of PAD,” GM of image-guided therapy devices Chris Landon said in a news release. “Stellarex is the only low-dose drug-coated balloon with a proven treatment effect at three years compared to the existing standard of care in the U.S. and Europe. By expanding our range of Stellarex balloons, we are adding to the treatment options that physicians can use to provide optimal care for each patient with peripheral arterial disease.”

Shares of PHG were down –0.2% at $43.10 per share in midday trading today.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA, Royal Philips

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS